FFF Enterprises Inc.
FFF Enterprises Inc. Adds COVID-19 Vaccines and Respiratory Syncytial Virus (RSV) Products to Its Comprehensive, Expanding Portfolio
13 sept. 2023 13h34 HE | FFF Enterprises.com
TEMECULA, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, has partnered with...
Icosavax_Logo.jpg
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14 août 2023 16h05 HE | Icosavax, Inc.
- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept...
Icosavax_Logo.jpg
Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential
08 août 2023 16h05 HE | Icosavax, Inc.
- In new data from Icosavax’s IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) - ...
Icosavax_Logo.jpg
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
20 juin 2023 08h00 HE | Icosavax, Inc.
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) --...
Icosavax_Logo.jpg
Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update
10 mai 2023 16h05 HE | Icosavax, Inc.
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term...
ARIDIS_LOGO.png
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
26 avr. 2023 12h15 HE | Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice...
Icosavax_Logo.jpg
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
30 mars 2023 16h05 HE | Icosavax, Inc.
- FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate - - Completed dosing in ongoing Phase 1 study of...
Image w slogan.png
New Technology Can Now Test for Airborne COVID and Several Strains of the Common Flu
01 mars 2023 23h35 HE | AirAnswers Inc
NORTH CHICAGO, Ill., March 01, 2023 (GLOBE NEWSWIRE) -- AirAnswers, the leader in air sampling and testing technology, is expanding their test offering to include a panel of airborne viruses...
Icosavax_Logo.jpg
Icosavax to Participate in the Upcoming Healthcare Conferences
28 févr. 2023 08h00 HE | Icosavax, Inc.
SEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax_Logo.jpg
Icosavax Granted FDA Fast Track Designation for IVX-A12
21 févr. 2023 08h00 HE | Icosavax, Inc.
SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...